Media Coverage | Pharmazz, Inc.

Pharmazz Chairman and CEO Dr. Anil Gulati’s IPC-IPSCON 2024 session sheds light on revolutionary stroke treatment, Sovateltide

by APN NEWS on Nov 30, 2024 -- Pharmazz, Inc., a late-stage biopharmaceutical company addressing the critical care market, showcased the groundbreaking potential of its lead drug, Sovateltide, at the International Pharmacology Conference & 54th Annual Conference of Indian Pharmacological Society (IPC-IPSCON 2024). Organized by the Department of Pharmacology at AIIMS, New Delhi, on November 29, this prestigious event featured an oral presentation by Dr. Anil Gulati, Chairman and Chief Executive Officer of Pharmazz, Inc., Willowbrook, Illinois, USA. His session, titled “Successful development of a pharmacological concept to treat cerebral stroke patients,” highlighted pivotal Phase 3 trial results from India.

Centhaquine set to enter US-FDA approved Phase 3 clinical trial in US and Europe

By EP News Bureau On Aug 2, 2023 -- Centhaquine, a first-in-class drug developed by Pharmazz India, a majority-owned subsidiary of Pharmazz, has received approval from the US-FDA to enter phase 3 clinical trials in the US and the EU. Pharmazz, a Delaware Corporation based in Illinois, US is a biopharma company focused on discovering, acquiring, developing, and commercialising therapeutics that target critical care medicine...

First-ever Indian drug to get direct US FDA approval to enter ph 3 trials in US & EU

By BioSpectrum India On Aug 2, 2023 -- Pharmazz India, a majority-owned subsidiary of US-based Pharmazz, Inc.’s first-in-class drug developed in India, Centhaquine has become the first-ever Indian drug to get direct approval from the US Food and Drug Administration (FDA) to enter phase 3 clinical trials in the United States and the European Union (EU)...

Centhaquine to enter US FDA approved phase 3 clinical trial in US and Europe, says Pharmazz India

By Pharmabiz On Aug 2, 2023 -- Pharmazz India Private Limited, a majority-owned subsidiary of Pharmazz, Inc, has announced that its first-in-class drug developed in India, centhaquine has become the first-ever Indian drug to get direct approval from the US FDA to enter phase 3 clinical trials in the United States and the European Union...

Centhaquine set to enter US-FDA approved Phase 3 Clinical Trial in US and Europe

By FE Healthcare On Aug 2, 2023 -- According to the company’s press statement, the compound has already received the Manufacturing and Marketing Authorisation by Indian Regulatory Agency, CDSCO in May 2020.Pharmazz India Private Limited on Wednesday announced that it’s Centhaquine has become the first-ever Indian drug to get direct approval from the USFDA to enter phase 3 clinical trials in the United States and the European Union...

Recently Pharmazz India Private Limited presented its nine years of research done for developing life saving drugs

Mar. 19, 2019, - New Delhi, India.-- Recently Pharmazz India Pvt Ltd presented its nine years of research done for developing life saving drugs at a conference. These drugs will be helpful in cases of accidents, maternal mortality, diarrhoea and burns as these can control excessive blood loss or fluid loss from the patient’s body to such an extent that doctors can effectively...

रक्त बहने से होने वाली मौत रोकने की दवा ईजाद

Mar. 14, 2019, - New Delhi, India -- राज एक्सप्रेस, नई दिल्ली। वैज्ञानिकों ने करीब नौ वर्षों के शोध के बाद ऐसी दवाइयों को ईजाद किया है, जिससे अत्यधिक मात्रा में रक्त बहने से होने वाली मौत की रोकथाम में सहायक होंगी। ये दवाएं दुर्घटना, गर्भावस्था, आपरेशन आदि के समय अधिक मात्रा में रक्त निकल जाने से होने वाली मृत्यु को रोकने में मदद करेंगी।.

रक्त बहने से होने वाली मौत रोकने की दवा ईजाद

ar. 14, 2019, - New Delhi, India -- राज एक्सप्रेस, नई दिल्ली। वैज्ञानिकों ने करीब नौ वर्षों के शोध के बाद ऐसी दवाइयों को ईजाद किया है, जिससे अत्यधिक मात्रा में रक्त बहने से होने वाली मौत की रोकथाम में सहायक होंगी। ये दवाएं दुर्घटना, गर्भावस्था, आपरेशन आदि के समय अधिक मात्रा में रक्त निकल जाने से होने वाली मृत्यु को रोकने में मदद करेंगी।.

More Effective Drugs Developed for Hypovolemic Shock

Mar. 13, 2019. - New Delhi, India -- The company says considering the preclinical and clinical data till date, the chances of survival are very high. The drug has shown remarkable effects in patients of hypovolemic shock. Three most important surrogate clinical endpoints for hypovolemic shock are blood pressure, blood lactate and base-deficit, and our clinical phase II results demonstrate all three surrogate clinical points significantly (P<0.001) improved compared to standard of care.

रक्त बहने से होने वाली मौत रोकने की दवा ईजाद

Mar. 12, 2019, - New Delhi, India -- नई दिल्ली (एजेंसी)। वैज्ञानिकों ने करीब नौ वर्षों के शोध के बाद ऐसी दवाइयों को ईजाद किया है जो अत्यधिक मात्रा में रक्त बह जाने से होने वाली मौत की रोकथाम में सहायक होंगी। ये दवायें दुर्घटना, गर्भावस्था, आपरेशन आदि के समय अधिक मात्रा में रक्त निकल जाने से होने वाली मृत्यु को रोकने में मदद करेंगी। फारमाज इंडिया प्राइवेट लिमिटेड ने ‘फारमाज इन्वेस्टिगेटर्स मीटिंग’ का आयोजन किया जिसका मुख्य उद्देश्य उन दवाओं की शोध की जानकारी देना था जिनके माध्यम से ऐसी दवाओं का निर्माण हो रहा है।.

रक्त बहने से होने वाली मौत रोकने की दवा ईजाद

Mar. 12, 2019, - New Delhi, India -- नई दिल्ली। वैज्ञानिकों ने करीब नौ वर्षों के शोध के बाद ऐसी दवाइयों को ईजाद किया है, जिससे अत्यधिक मात्रा में रक्त बहने से होने वाली मौत की रोकथाम में सहायक होंगी। ये दवाएं दुर्घटना, गर्भावस्था, आपरेशन आदि के समय अधिक मात्रा में रक्त निकल जाने से होने वाली मृत्यु को रोकने में मदद करेंगी। ये दवाएं दुर्घटना, गर्भावस्था और आपरेशन के दौरान करेंगी मदद.

Prevention of death from excess bleeding

Feb. 07, 2019, - NAPERVILLE, Ill., Feb. 7, 2019 /PRNewswire/ -- Pharmazz, Inc., today announced that data from the Phase 2 clinical study in patients with acute cerebral ischemic stroke, were presented in the late breaking Multicenter, Ongoing Clinical Trials Posters II (Board CTP27) session at the International Stroke Conference 2019 in Honolulu, Hawaii February 6-8, 2019...

Pharmazz India Private Limited shared their research on life saving drugs

Nov. 12, 2018, - NAPERVILLE, Ill., Nov. 12, 2018 /PRNewswire/ -- Pharmazz, Inc., today announced that data from the Phase 2 clinical study in patients with hypovolemic shock, were presented in the Drug Discovery-Heart Failure Oral Abstracts Session II at the American Heart Association Scientific Sessions in Chicago November 12, 2018.